1.JPG)
Acquired Orphan Blood Disease Market Size is valued at USD 9.4 Billion in 2024 and is predicted to reach USD 26.1 Billion by the year 2034 at a 10.8% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Insufficient red blood cells in the circulation results in acquired orphan blood disease, a rare type of rare blood illness. The inability of the body to manufacture red blood cells is a defining feature of this illness. Additionally, poor bone marrow function lowers the number of platelets by reducing the number of red blood cells in the blood. This drop in platelet count brings on anemia and thrombosis. Less red blood cells are present in anemia, a blood disorder.
The most frequent cause of anemia is blood loss, which also has chronic effects. Globally increasing rates of chronic sickness will likely raise the demand for effective healthcare treatments and provide new market opportunities for acquired orphan blood diseases. People's increased awareness of healthcare-related issues in recent years is also anticipated to increase demand in the global market. The medical industry's improved technological advancements also foster new market expansion chances. Developing country citizens currently earn significantly more per capita, which enhances their capacity to invest more money in advanced healthcare choices. The contributing element will likely increase the market for acquired orphan blood disorders.
Furthermore, it is anticipated that strict regulatory guidelines will limit market expansion chances in the coming years. It is also predicted that fewer investments by industry participants in these uncommon diseases will hinder market development drivers. Additionally, the market entry of new companies is anticipated to be hampered by the increasing number of consolidations.
The acquired orphan blood disease market is segmented on the therapy, disease indication and distribution channel. Based on therapy, the market is segmented into recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists and others. Based on disease indication, the acquired orphan blood disease market is segmented into acquired agranulocytosis, acquired hemophilia, acquired von Willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome and others. Based on distribution channel, the acquired orphan blood disease market is segmented into hospital pharmacies, retail pharmacies and others.
Based on disease indication, the acquired orphan blood disease market is segmented into acquired agranulocytosis, acquired hemophilia, acquired von Willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome and others. The acquired hemophilia category grabbed the highest revenue share, and it is anticipated that it will continue to hold that position during the anticipated time. Patients with acquired hemophilia (A.H.), a rare autoimmune illness characterized by bleeding without having a personal or family history of clotting or coagulation disorders, experience bleeding. When the body's immune system unintentionally targets healthy cells or tissue, autoimmune diseases result.
Based on distribution channel, the acquired orphan blood disease market is segmented into hospital pharmacies, retail pharmacies and others. The hospital pharmacy category is anticipated to grow significantly over the forecast period due to the increased quantity of medications being given by trained healthcare professionals in the hospital. The rise is linked to SMA's high rate of hospitalization. Due to the significant risk of respiratory problems and scoliosis, hospitals treat most patients. Additionally, residents of emerging nations are already earning much more per capita, increasing their ability to invest more money in high-quality healthcare options and fueling the expansion of the hospital pharmacy market.
North America's acquired orphan blood disease market is expected to register the highest market share in revenue shortly due to the region's rising rate of blood-related diseases. It is also anticipated that increased healthcare insurance alternatives and R&D spending, notably in the U.S., on innovative medications will impact the region's market expansion prospects. The market in North America is expected to grow at a significant rate in the years to come since sophisticated and organized healthcare solutions are readily available. Additionally, the Asia Pacific is anticipated to expand significantly over the forecast period due to the government's growing efforts for efficient healthcare facilities, and the construction of the healthcare infrastructure is responsible for the surge. The demand for regional goods and services is predicted to rise as patient populations rise.
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 9.4 Billion |
|
Revenue forecast in 2034 |
USD 26.1 Billion |
|
Growth rate CAGR |
CAGR of 10.8 % from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Therapy, Disease Indication, Distribution Channel |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Alexion Pharmaceuticals, Inc., Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Sanofi S.A., GlaxoSmithKline plc., Cyclacel Pharmaceuticals, Inc., Onconova Therapeutics, Inc., Incyte Corporation and CTI BioPharma Corp. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Acquired Orphan Blood Disease Market Snapshot
Chapter 4. Global Acquired Orphan Blood Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Therapy Estimates & Trend Analysis
5.1. by Therapy & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapy:
5.2.1. Recombinant Factor
5.2.2. Immunoglobulin Infusion Therapy
5.2.3. Activated Prothrombin Complex Concentrate
5.2.4. Thrombopoietin Receptor Agonists
5.2.5. Others
Chapter 6. Market Segmentation 2: by Disease Indication Estimates & Trend Analysis
6.1. by Disease Indication & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Disease Indication:
6.2.1. Acquired Agranulocytosis
6.2.2. Acquired Hemophilia
6.2.3. Acquired Von Willebrand Syndrome
6.2.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
6.2.5. Myelodysplastic Syndrome
6.2.6. Other
Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis
7.1. by Distribution Channel & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel:
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.2.3. Others
Chapter 8. Acquired Orphan Blood Disease Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
8.1.2. North America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2021-2034
8.1.3. North America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
8.1.4. North America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
8.2.2. Europe Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2021-2034
8.2.3. Europe Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2023-2031
8.2.4. Europe Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
8.3.2. Asia Pacific Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2021-2034
8.3.3. Asia-Pacific Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
8.3.4. Asia Pacific Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
8.4.2. Latin America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2021-2034
8.4.3. Latin America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
8.4.4. Latin America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2021-2034
8.5.2. Middle East & Africa Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2021-2034
8.5.3. Middle East & Africa Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
8.5.4. Middle East & Africa Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Alexion Pharmaceuticals, Inc.
9.2.2. Amgen, Inc.
9.2.3. Celgene Corporation
9.2.4. Eli Lilly and Company
9.2.5. Sanofi S.A.
9.2.6. GlaxoSmithKline plc.
9.2.7. Cyclacel Pharmaceuticals, Inc.
9.2.8. Onconova Therapeutics, Inc.
9.2.9. Incyte Corporation
9.2.10. CTI BioPharma Corp.
9.2.11. Other Prominent Players
By Therapy-
By Disease Indication-
By Distribution Channel-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
